pacritinib

This page shows the latest pacritinib news and features for those working in and with pharma, biotech and healthcare.

CTI slumps as Servier-partnered lymphoma drug fails

Thankfully for CTI, it’s been making progress on main pipeline candidate pacritinib, an orally-active kinase inhibitor that targets JAK2, FLT3, IRAK1 and CSF1R and is in phase III testing ... Pacritinib has had its own share of problems, however,

Latest news

Baxalta and CTI complete filing for Jakafi rival in US

Baxalta and CTI complete filing for Jakafi rival in US. Myelofibrosis candidate pacritinib aiming for accelerated approval. ... Baxalta's former parent company Baxter licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m.
Baxter and CTI's Jakafi rival clears phase III trial

Baxter and CTI's Jakafi rival clears phase III trial. Myelofibrosis candidate pacritinib moves closer to market. ... Baxter licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m deal.
Jakafi cleared for bone marrow disorder by FDA

pacritinib. Sanofi was forced to discontinue development of its fedratinib (SAR302503) candidate after cases of a rare form of encephalopathy were seen in late-stage trials.
Baxter licenses cancer drug from CTI in $172m deal

Baxter licenses cancer drug from CTI in $172m deal. Pacritinib is being investigated to treat blood disorder myelofibrosis. ... he added, noting that additional data on pacritinib will be presented at the American Society of Haematology (ASH) conference
Sanofi pulls development of blood cancer drug

Therapeutics/Baxter's pacritinib.

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Pharma deals in August 2015

Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib.
Deal Watch table for November 2013

232. Cell Therapeutics / Baxter. Licence. JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase.
Pharma deals during November 2013

Cell Therapeutics' experimental JAK2/FLT3 inhibitor, pacritinib. ... Pacritinib, an oral therapy, is currently in phase III development for patients with myelofibrosis and has activity against genetic mutations linked to myelofibrosis, leukaemia and

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Delivery Manager/ Head of Delivery – Executive Search: Neg

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Home based, Principal Medical Writer, Medical Communications: Excellent package

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Editorial Director – Medical Education (MedComms): Neg

Senior Account Manager: Competitive salary commensurate with experience

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Home based, Chief Medical Writer, Medical Communications: Excellent package

Client Services Director – Healthcare Advertising - London: Neg

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Home based, Senior Medical Writer, Medical Communications: Excellent package

Home based, Editorial Team Leader, Medical Communications: Excellent package

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Business Unit Head, Medical Communications, London: Excellent package

Client Services Director - Med Comms: Great salary and bebefits

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Account Manager: £40, 000 - £45, 000 benefits

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Subscribe to our email news alerts

PMHub

Add my company

Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....